Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
2
×
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
deals
detroit blog main
detroit top stories
gene therapy
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
2
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
2
×
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
adalimumab (humira)
aducanumab
aduro biotech
affordable care act
alez azar
alnylam pharmaceuticals
alzheimer's disease
ambys medicines
amicus therapeutics
ampio pharmaceuticals
What
bio
drug
news
road
2
×
roundup
approval
aren’t
biogen’s
biopharmaceutical
companies
convo
developers
drugs
earlier
failures
fda
gene
help
imminent
littered
long
medicare
moves
nash
new
noteworthy
patients
price
prices
remains
rulings
separate
strategy
talk
therapy
they’ll
winding
Language
Current search:
road
×
photo
×
" texas blog main "
×
" raleigh-durham top stories "
×
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
6 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More